PDF(Pubmed)
Abstract：
UNASSIGNED: Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many misconceptions by clinicians and patients accompany this medication. We aimed to review the most common \"false myths\" regarding TRD and esketemine, counterarguing with evidence-based facts.
UNASSIGNED: The keywords \"esketamine\", \"treatment resistance depression\", \"depression\", \"myth\", \"mythology\", \"pharmacological treatment\", and \"misunderstanding\" were entered in the main databases and combined through Boolean operators.
UNASSIGNED: Misconceptions regarding the TRD prevalence, clinical features and predictors have been found. With respect of esketamine, criteria to start treatment, dissociative symptoms, potential addiction and aspects of administration and monitoring, were found to be affected by false beliefs by clinicians and patients.
UNASSIGNED: TRD represents a challenging condition, requiring precise diagnosis in order to achieve patient\'s full recovery. Esketamine has been proved as an effective medication to treat TRD, although it requires precautions. Evidence can inform clinical practice, in order to offer this innovative treatment to all patients with TRD.
UNASSIGNED: The keywords \"esketamine\", \"treatment resistance depression\", \"depression\", \"myth\", \"mythology\", \"pharmacological treatment\", and \"misunderstanding\" were entered in the main databases and combined through Boolean operators.
UNASSIGNED: Misconceptions regarding the TRD prevalence, clinical features and predictors have been found. With respect of esketamine, criteria to start treatment, dissociative symptoms, potential addiction and aspects of administration and monitoring, were found to be affected by false beliefs by clinicians and patients.
UNASSIGNED: TRD represents a challenging condition, requiring precise diagnosis in order to achieve patient\'s full recovery. Esketamine has been proved as an effective medication to treat TRD, although it requires precautions. Evidence can inform clinical practice, in order to offer this innovative treatment to all patients with TRD.
摘要：
■当至少两种不同的抗抑郁药，以正确的剂量服用，足够的时间和连续性，无法产生积极的临床效果。Esketamine,氯胺酮的S-对映体，最近被美国食品和药物管理局和欧洲药品管理局批准用于TRD治疗。尽管临床疗效证明,这种药物伴随着临床医生和患者的许多误解。我们旨在回顾关于TRD和esketemine的最常见的“虚假神话”，以证据为基础的事实反驳。
■关键字\"esketamine\",“治疗抵抗抑郁症”，“抑郁症”，\"神话\",“神话”，“药物治疗”，和“误解”在主要数据库中输入，并通过布尔运算符组合。
■关于TRD患病率的误解，已发现临床特征和预测因子。关于艾氯胺酮,开始治疗的标准，分离症状，潜在的成瘾以及管理和监测方面，被发现受到临床医生和患者错误信念的影响。
■TRD代表一个具有挑战性的条件，需要精确的诊断，以实现患者的完全康复。Esketamine已被证明是治疗TRD的有效药物，尽管它需要预防措施。证据可以为临床实践提供信息，为了为所有TRD患者提供这种创新的治疗方法。
■关键字\"esketamine\",“治疗抵抗抑郁症”，“抑郁症”，\"神话\",“神话”，“药物治疗”，和“误解”在主要数据库中输入，并通过布尔运算符组合。
■关于TRD患病率的误解，已发现临床特征和预测因子。关于艾氯胺酮,开始治疗的标准，分离症状，潜在的成瘾以及管理和监测方面，被发现受到临床医生和患者错误信念的影响。
■TRD代表一个具有挑战性的条件，需要精确的诊断，以实现患者的完全康复。Esketamine已被证明是治疗TRD的有效药物，尽管它需要预防措施。证据可以为临床实践提供信息，为了为所有TRD患者提供这种创新的治疗方法。
